GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Posted by Brian Himes on Aug 7th, 2026

GH Research (NASDAQ:GHRS – Get Free Report) had its price objective hoisted by analysts at Cantor Fitzgerald from $35.00 to $40.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 30.55% from the company’s current price.

Several other equities research analysts also recently weighed in on the stock. Citizens Jmp cut their target price on shares of GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a research note on Friday, May 15th. Citigroup restated an “outperform” rating on shares of GH Research in a research note on Friday, May 15th. HC Wainwright reduced their price objective on GH Research from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Zacks Research lowered GH Research from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Finally, Wells Fargo & Company assumed coverage on GH Research in a research note on Monday, July 27th. They set an “overweight” rating and a $44.00 target price for the company. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.11.

Get Our Latest Stock Report on GH Research

GH Research Trading Up 5.2%

GHRS opened at $30.64 on Friday. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -33.30 and a beta of 1.29. The stock’s 50-day moving average price is $25.57 and its 200 day moving average price is $20.09. GH Research has a 12-month low of $11.32 and a 12-month high of $31.00.

GH Research (NASDAQ:GHRS – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.06. On average, research analysts forecast that GH Research will post -1.46 earnings per share for the current year.

Institutional Trading of GH Research

Institutional investors have recently bought and sold shares of the business. Royal Bank of Canada boosted its stake in GH Research by 43.1% in the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after acquiring an additional 780 shares in the last quarter. Barclays PLC lifted its position in GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after acquiring an additional 822 shares during the period. North Star Investment Management Corp. acquired a new position in shares of GH Research in the first quarter valued at approximately $31,000. Osaic Holdings Inc. lifted its holdings in shares of GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the period. Finally, Jefferies Financial Group Inc. increased its stake in GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after buying an additional 2,988 shares during the period. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

(Get Free Report)

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.